118 research outputs found
Vesnarinone and glucocorticoids cooperatively induce G1 arrest and have an anti-tumour effect on human non-small cell lung carcinoma cells grown in nude mice
EAN consensus statement for management of patients with neurological diseases during the COVIDâ19 pandemic
Background and purpose
The recent SARSâCoVâ2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fastâevolving pandemic, evidenceâbased studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVIDâ19.
Methods
A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP coâchairs rated importance on a fiveâpoint Likert scale. Results were graded by importance and reported as consensus statements.
Results
In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fiftyânine statements obtained >70% agreement and were retained. In round three, responses were received from 55 coâchairs of 29 SPs. Whilst general recommendations related to prevention of COVIDâ19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy.
Conclusion
This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVIDâ19 pandemic that provides immediate guidance for neurologists. In this fastâevolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges
Documenti dall'Archivio della Regia Scuola superiore di medicina veterinaria di Milano
Glutamic acid as a precursor to n-terminal pyroglutamic acid in mouse plasmacytoma protein.
Cell suspensions derived from a mouse plasmacytoma (RPC-20) that secretes an immunoglobulin light chain containing N-terminal pyroglutamic acid can synthesize protein in vitro. Chromatographic examination of an enzymatic digest of protein labeled with glutamic acid shows only labeled glutamic acid and pyroglutamic acid; hydrolysis of protein from cells labeled with glutamine, however, yields substantial amounts of glutamic acid in addition to glutamine and pyroglutamic acid. The absence of glutamine synthetase and presence of glutaminase in plasmacytoma homogenates is consistent with these findings. These data indicate that N-terminal pyroglutamic acid can be derived from glutamic acid without prior conversion of glutamic acid to glutamine. Since free or bound forms of glutamine cyclize nonezymatically to pyroglutamate with ease, while glutamic acid does not, the data suggest that N-terminal pyroglutamic acid formation from glutamic acid is enzymatic rather than spontaneous
Glutamic Acid as a Precursor to N-Terminal Pyroglutamic Acid in Mouse Plasmacytoma Protein
Glutamic acid as a precursor to n-terminal pyrrolidone corboxylic acid in mouse plasmacytoma protein. Abstr.
- âŠ